JPWO2022125982A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022125982A5
JPWO2022125982A5 JP2023534899A JP2023534899A JPWO2022125982A5 JP WO2022125982 A5 JPWO2022125982 A5 JP WO2022125982A5 JP 2023534899 A JP2023534899 A JP 2023534899A JP 2023534899 A JP2023534899 A JP 2023534899A JP WO2022125982 A5 JPWO2022125982 A5 JP WO2022125982A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552816A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062946 external-priority patent/WO2022125982A1/en
Publication of JP2023552816A publication Critical patent/JP2023552816A/ja
Publication of JPWO2022125982A5 publication Critical patent/JPWO2022125982A5/ja
Pending legal-status Critical Current

Links

JP2023534899A 2020-12-11 2021-12-10 細胞内のmhcクラスiiを低減する組成物及び方法 Pending JP2023552816A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063124064P 2020-12-11 2020-12-11
US63/124,064 2020-12-11
US202063130106P 2020-12-23 2020-12-23
US63/130,106 2020-12-23
PCT/US2021/062946 WO2022125982A1 (en) 2020-12-11 2021-12-10 Compositions and methods for reducing mhc class ii in a cell

Publications (2)

Publication Number Publication Date
JP2023552816A JP2023552816A (ja) 2023-12-19
JPWO2022125982A5 true JPWO2022125982A5 (enrdf_load_stackoverflow) 2024-12-19

Family

ID=80168106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534899A Pending JP2023552816A (ja) 2020-12-11 2021-12-10 細胞内のmhcクラスiiを低減する組成物及び方法

Country Status (13)

Country Link
US (1) US20240016934A1 (enrdf_load_stackoverflow)
EP (1) EP4259783A1 (enrdf_load_stackoverflow)
JP (1) JP2023552816A (enrdf_load_stackoverflow)
KR (1) KR20230130635A (enrdf_load_stackoverflow)
AU (1) AU2021396403A1 (enrdf_load_stackoverflow)
CA (1) CA3204997A1 (enrdf_load_stackoverflow)
CL (2) CL2023001688A1 (enrdf_load_stackoverflow)
CO (1) CO2023008922A2 (enrdf_load_stackoverflow)
CR (1) CR20230303A (enrdf_load_stackoverflow)
IL (1) IL303505A (enrdf_load_stackoverflow)
MX (1) MX2023006878A (enrdf_load_stackoverflow)
TW (1) TW202235617A (enrdf_load_stackoverflow)
WO (1) WO2022125982A1 (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4544058A1 (en) * 2022-06-23 2025-04-30 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of ciita expression
US20240189355A1 (en) * 2022-11-14 2024-06-13 WUGEN, Inc. Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use
CN118922551A (zh) * 2023-01-30 2024-11-08 南京北恒生物科技有限公司 用于CRISPR-Cas基因编辑系统的方法及组合物
TW202515992A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對轉形生長因子β受體2型(TGFβR2)進行基因修飾之組合物及方法
WO2025038642A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying cd70
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025038646A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Cd70 car-t compositions and methods for cell-based therapy
WO2025049481A1 (en) * 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods of editing an hla-a gene in vitro
WO2025049432A1 (en) * 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
EP1044987B1 (en) 1991-12-24 2006-02-15 Isis Pharmaceuticals, Inc. Gapped 2'-modified oligonucleotides
AU2522095A (en) 1994-05-19 1995-12-18 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
CN103668470B (zh) 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
WO2014099744A1 (en) 2012-12-17 2014-06-26 President And Fellows Of Harvard College Rna-guided human genome engineering
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EA201891338A1 (ru) * 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
US20190136231A1 (en) 2016-03-30 2019-05-09 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EA201991369A1 (ru) 2016-12-08 2019-12-30 Интеллиа Терапьютикс, Инк. Модифицированные направляющие рнк
AU2018266698A1 (en) 2017-05-08 2019-11-28 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
CA3062506A1 (en) * 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
SMT202400172T1 (it) 2017-09-29 2024-07-09 Intellia Therapeutics Inc Formulazioni
WO2019118516A1 (en) * 2017-12-11 2019-06-20 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
WO2019147805A2 (en) 2018-01-26 2019-08-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatory t cells targeted with chimeric antigen receptors
EP3775229A4 (en) 2018-03-27 2021-12-15 The Trustees Of The University Of Pennsylvania MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTION AND SCREENING METHODS TO IDENTIFY THEM
JP2021526804A (ja) 2018-06-08 2021-10-11 インテリア セラピューティクス,インコーポレイテッド 遺伝子編集のための修飾されたガイドrna
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CN113166743A (zh) 2018-10-15 2021-07-23 马萨诸塞大学 Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑
EP3867379A1 (en) 2018-10-16 2021-08-25 Intellia Therapeutics, Inc. Compositions and methods for immunotherapy
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
EP3924375A4 (en) * 2019-02-15 2023-03-22 President and Fellows of Harvard College Universal donor stem cells and related methods

Similar Documents

Publication Publication Date Title
JP2024116190A5 (enrdf_load_stackoverflow)
JP2022184985A5 (enrdf_load_stackoverflow)
JP2023166402A5 (enrdf_load_stackoverflow)
JP2024114921A5 (enrdf_load_stackoverflow)
JP2021184963A5 (enrdf_load_stackoverflow)
JP2024059739A5 (enrdf_load_stackoverflow)
JP2024036694A5 (enrdf_load_stackoverflow)
JP2024032941A5 (enrdf_load_stackoverflow)
JP2023145572A5 (enrdf_load_stackoverflow)
JP2024161376A5 (enrdf_load_stackoverflow)
JP2023181322A5 (enrdf_load_stackoverflow)
JP2024129139A5 (enrdf_load_stackoverflow)
JP2024045126A5 (enrdf_load_stackoverflow)
JP2024112817A5 (enrdf_load_stackoverflow)
JP2024099716A5 (enrdf_load_stackoverflow)
JP2024149687A5 (enrdf_load_stackoverflow)
JP2023093656A5 (enrdf_load_stackoverflow)
JP2023085264A5 (enrdf_load_stackoverflow)
JP2023078173A5 (enrdf_load_stackoverflow)
JP2024099585A5 (enrdf_load_stackoverflow)
JP2024170456A5 (enrdf_load_stackoverflow)
JP2024073452A5 (enrdf_load_stackoverflow)
JP2024063214A5 (enrdf_load_stackoverflow)
JPWO2020252375A5 (enrdf_load_stackoverflow)
JP2025032231A5 (enrdf_load_stackoverflow)